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Edited by Varda RotterAbstract We identiﬁed a novel inhibitor of growth family mem-
ber 2 (ING2) isoform, ING2b, which shares exon 2 with ING2a,
but lacks the N-terminal p53 binding region. Contrary to
ING2a, ING2bs promoter has no p53 binding sites. Consis-
tently, activation of p53 led to suppression of ING2a, leaving
ING2b unaﬀected. Through isoform-speciﬁc targeting, we
showed that ING2a knockdown suppressed cell growth only in
the presence of p53, ING2b knockdown had no eﬀect on cell
growth, and knockdown of both induced cell cycle arrest and
apoptosis independently of p53. ING2a and ING2b have com-
pensatory roles that protect cells from cell cycle arrest and apop-
tosis and may be involved in development of chemotherapeutic
resistance.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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ING2 shares the highest amino acid homology with ING1
among the inhibitor of growth (ING) protein family members
[1]. So far, ﬁve isoforms of ING1 that have diﬀerent abilities on
apoptosis and cell proliferation have been reported [2]. How-
ever no isoforms of ING2 have been reported despite the sim-
ilarity observed between ING1 and ING2.
ING2 binds to H3K4me3 with mSin3A-HDAC1 complex
[3–5]. Wang et al. [6] showed that a leucine zipper-like motif
at the N-terminal end of ING2 is critical for its association
with p53 and modulation of p53-mediated chromatin remodel-
ing. Recently, Kumamoto et al. [7] showed that the ING2
promoter has two p53 binding sites through which p53
down-regulates expression of ING2. Moreover, suppression
of ING2 induced p53 dependent senescence in normal humanAbbreviation: ING, the inhibitor of growth
q The nucleotide sequence(s) reported in this paper has been submit-
ted to the DDBJ/GenBankTM/EBI Data Bank with Accession Nos.
AB196793 (human ING2b) and AB433625 (mouse ING2b).
*Corresponding author. Fax: +1 301 496 0497.
E-mail address: Curtis_Harris@nih.gov (C.C. Harris).
0014-5793/$34.00 Published by Elsevier B.V. on behalf of the Federation of
doi:10.1016/j.febslet.2008.10.024ﬁbroblasts. Thus ING2 seems to have crucial roles in tran-
scriptional regulation of various genes.
Here, we report a novel ING2 isoform, ING2b. We found
diﬀerent transcriptional regulation of ING2a and ING2b by
p53, and feedback between p53 and ING2a, but not ING2b.
Using siRNA that targeted ING2a or ING2b speciﬁcally, or
both, we found that ING2a and ING2b have compensatory
roles that protect cells from cell cycle arrest or apoptosis. Be-
cause concurrent knockdown of ING2a and ING2b induced
cell cycle arrest or apoptosis in cancer cells regardless of p53
status, our results may encourage the development of new
therapeutic approaches directed to overcome clinical resistance
to chemotherapy.2. Materials and methods
2.1. Tissues and cell lines
cDNA from various tissues (Human Multiple Tissue cDNA Panel 1
and 2) were obtained from BD Bioscience (Palo Alto, CA). All cell
lines were obtained from ATCC (Manassas, VA) except for the
hTERT-immortalized cell line, NHF-hTERT, and isogenic cell line
pairs of lung adenocarcinoma A549. NHF-hTERT was derived by
infecting the primary cell strain GM07532 (Coriell Cell Repositories)
with a telomerase-expressing retrovirus [7]. Isogenic cell line pairs of
wild type (wt) p53-expressing A549 cells featuring a short-hairpin
shRNA sequence against human p53 (A549 p53KD) or a scrambled
(A549 SC) sequence were established in our laboratory [8] and cultured
in media containing 1 lg/ll puromycin (Sigma, St Louis, MO).
2.2. Determination of the transcriptional starting site of ING2b
We determined the transcriptional starting site of ING2b by 5 0
RLM-RACE (FirstChoice RACE-Ready cDNA: human testis and
placenta, Ambion, Austin, TX). We used adapter-speciﬁc outer and in-
ner primers, an ING2b-speciﬁc outer and inner primers (5 0-GGAAA-
GAGGTTGGAAACATCA-3 0 and 5 0-TGCAAACCCCGATTCG-
GACT-3 0, respectively). We performed the ﬁrst and second PCR
according to manufacturers protocol. The second PCR product was
separated in 2% agarose gel. A unique, distinct PCR band was
extracted, and its sequence was determined.
2.3. Plasmids and reagents
ING2b cDNA was ampliﬁed by PCR using KOD-Plus polymerase
(Novagen, Madison, WI) and cloned into pFLAG-CMV-6c (Sigma).
Lipofectamine Reagent (Invitrogen) was used for all plasmid transfec-
tions, according to manufacturers instructions. The following antibod-
ies were used for Western blotting or immunoﬂuorescence: anti-FLAG
monoclonal M2 (Sigma); anti-p53 monoclonal antibody DO-1 (Santa
Cruz); anti-b-actin mouse monoclonal AC-15 (Sigma).European Biochemical Societies.
M. Unoki et al. / FEBS Letters 582 (2008) 3868–3874 38692.4. Indirect immunoﬂuorescence assay
Cells were cultured on coverslips in 6-well plates and transfected
with plasmid constructs. After 24 h, FLAG-tagged proteins were visu-
alized as previously described [9] using Alexa Fluor 488 phalloidin
probe for detecting F-actin (Molecular probes, Invitrogen) and anti-
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For speciﬁc detection of ING2a and ING2b, ING2a and ING2b-spe-
ciﬁc forward primers (5 0-GACATGCAGAGGAACGTGTCT-3 0 and
5 0-TGGATCAGGACGGCGATCAG-3 0, respectively), ING2a and
ING2b common reverse primer (5 0-GAGAAGCTGCTGTAGACG-
TTTC-3 0), and ING2a and ING2b common probe (5 0-FAM-CTTA-Exon 1b Exon 2
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RA-3 0) were designed. The PCR products were followed real-time
using ABI PRISM 7700 Sequence Detection System (Applied Biosys-
tems, Foster City, CA) for 40 cycles. b2-microglobulin was used for
normalization (4310886E, Applied Biosystems).
2.6. Nutlin-3a and adriamycin treatment
Nutlin-3a was a generous gift from Dr. Lyubomir Vassilev (Hoﬀ-
mann-La Roche Inc., Nutley, NJ). Nutlin-3a was dissolved in DMSO
and added at 10 lM. For control, cells were treated with DMSO alone.
Adriamycin (Sigma) was used at 1 lg/ml. Cells were harvested after
exposure to the drugs for 24 h and total RNA was isolated and re-
verse-transcribed by a general method using Trizol Reagent (Invitro-
gen) and SuperScriptIII First-Strand Synthesis System (Invitrogen).
2.7. siRNA interference
We designed siRNAs that can selectively knock down ING2a or
ING2b. We also designed one siRNA sequence that targets both
ING2a and ING2b (ING2 common siRNA). The targeting sequences
of these siRNAs are as follows: ING2a-speciﬁc siRNA targeting se-
quence; 5 0-CAACAAAUAUCAAGAAACGUU-3 0, ING2b-speciﬁc
siRNA targeting sequence; 5 0-GGUGAUGUUUCCAACCUCUUU-
3 0, and ING2 common siRNA targeting sequence; 5 0-ACAGUGU-
UUCCAAGAUCCTGCUGAA-30. The non-speciﬁc siRNA sequence
used was 5 0-AAUUCUCCGAACGUGUCACGU-3 0 (Qiagen, Valen-
cia, CA). These siRNAs were transfected at a ﬁnal concentration of
20 nM using Lipofectamine 2000 reagent (Invitrogen) according to
the manufacturers protocol. The siRNA transfection eﬃciency under
these conditions was 100%, as evaluated by a ﬂuorescent siRNA (data
not shown).
2.8. Growth assay
Cells were transfected with siRNAs twice, on the ﬁrst and fourth
days. Cell numbers were counted using Cell Counting Kit-8 (Dojindo
Molecular Technologies, Gaithersburg, MD) on the sixth day.
2.9. Flow cytometry and TUNEL assay
Cells were transfected with siRNAs twice, on the ﬁrst and fourth
days. After 6 days, ﬂow cytometry and TUNEL assay was performed
as previously described [10].3. Results
3.1. Identiﬁcation of a novel isoform of ING2, ING2b
We identiﬁed a novel ING2 isoform, ING2b (GenBank
Accession No: AB196793), by EST search using the BLASTRe
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Fig. 2. Expression levels of ING2a and ING2b in various tissues and cell lines
ING2b primer sets was the same between ING2a and ING2b (see Supplemeprogram (NCBI). We renamed the original ING2, as ING2a
in this report (DDBJ accession number: AF053537). The tran-
scriptional starting site of ING2b was determined by 5 0-RLM-
RACE in the intron 1 of ING2a using full length cDNAs from
testis and placenta. The predicted molecular weights of ING2a
and ING2b are 33 kDa and 28 kDa, respectively. In contrast
to the ING2a promoter that has two p53 binding sites through
which p53 suppresses its expression [7], we did not ﬁnd any
apparent p53 binding sites on the ING2b promoter. Instead,
a HSF1 and HSF2 binding site, a C-Rel binding site, a SP1
binding site, ﬁve MZF1 binding sites, and a p300 binding site
were predicted in the promoter region by TFSEARCH (http://
mbs.cbrc.jp/research/db/TFSEARCH.html). Among these
binding sites, the HSF1 and HSF2 binding site and the C-
Rel binding site are unique in the ING2b promoter (Fig. 1A).
ING2a and ING2b share exon 2 (Fig. 1A), but diﬀer in their N-
terminal regions, which are encoded by exons 1a and 1b,
respectively (Fig. 1B). Exon 1b of ING2b encodes 18 unique
amino acids and exon 1a of ING2a encodes 58 unique amino
acids (Fig. 1B). No motif was predicted in the unique 18 amino
acids of ING2b. The N-terminal region of ING2b does not
show any homology with the N-terminal region of ING1 iso-
forms. ING2a has a leucine zipper domain and an intact
coiled-coil domain in its unique N-terminal region. These do-
mains are absent in ING2b. Mouse Ing2b sequence was also
identiﬁed ( Supplemental Fig. S1, DDBJ Accession No:
AB433625). Mouse Ing2b is transcribed from intron 1 of In-
g2a and encodes a truncated 20.3 kDa protein that does not
have a unique N-terminal sequence, leucine zipper domain,
or coiled-coil domain.
3.2. Subcellular localization of ING2b
After we checked expression of FLAG-tagged ING2a
and FLAG-tagged ING2b from the plasmid vectors by
Western blotting (Fig. 1C), subcellular localization of the
two isoforms are examined by immunoﬂuorescence. The
majority of ING2b localized at the nucleus, similarly to ING2a
(Fig. 1D). Both ING2a and ING2b possess two nucleolar-tar-
geting sequences, a RRQR motif and a KKKK motif in their
ﬁrst and third NLS, respectively [11], and localized at nucleoli
(Fig. 1B).Cell-lines
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We examined expression level of ING2a and ING2b in nor-
mal tissues and various cell lines by qRT-PCR, using two un-
ique forward primers on exon 1a or 1b, and a common reverse
primer and a probe on exon 2. Eﬃciency of ampliﬁcation using
the same number of plasmid molecules as templates was al-
most the same with either primer set (Supplemental Fig. S2).
Both genes were expressed ubiquitously in all tissues and cell
lines examined, although ING2a was expressed predominantly
(Fig. 2). We did not see any correlation between p53 status and
basal expression level of either ING2a or ING2b.
3.4. p53 Dependent suppression of ING2a, but not ING2b
We examined how p53 activation might diﬀerentially regu-
late ING2a and ING2b. We induced endogenous p53 stabiliza-R
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ﬁbroblasts.tion through nutlin-3a, an inhibitor of MDM2, or adriamycin,
a DNA intercalating drug used for cancer chemotherapy. A
pair of isogenic A549 cells with diﬀerent p53 status was ex-
posed to these agents. The A549 transfectants bearing scram-
ble shRNA, A549 SC, served as a control for normal level of
p53 expression. The A549 transfectants bearing p53 shRNA,
A549 p53KD, have very low expression of p53, and p53 is
not eﬃciently stabilized upon exposure to nutlin-3a or adria-
mycin (Supplemental Fig. S3A and B). We also treated four
other p53 wild type cell lines and three p53-mutant cell lines
with nutlin-3a. ING2a, but not ING2b, was down-regulated
upon exposure to nutlin-3a or adriamycin (Fig. 3A and B) only
in cells bearing wt p53, indicating that ING2b is not a direct
transcriptional target of p53. As expected, neither gene was
down-regulated by the treatment when wt p53 was absentR
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ined the expression level of ING2a and ING2b in young and
senescent MRC5 ﬁbroblasts. During senescence p53 becomes
post-translationally modiﬁed by acetylation ( Supplemental
Fig. S3C) and is activated. We found that ING2a was down-
regulated in MRC5 ﬁbroblasts undergoing senescence, but
ING2b was not changed (Fig. 3C).
3.5. Eﬀect of ING2a and ING2b knockdown on cell growth
Selectivity of ING2a-speciﬁc and ING2b-speciﬁc siRNAs
was evaluated by qRT-PCR using a panel of cancer cell lines
(Fig. 4A and B). Each siRNA led to reduced expression of
the cognate sequence, while leaving expression of the other
mRNA largely unaﬀected. A siRNA designed to target a
shared exon 2 sequence (ING2 common siRNA) suppressed
expression of both ING2a and ING2b. We then examined the
eﬀect of such siRNAs on cell growth, cell cycle and apoptosis
of a panel of cancer cell lines with diﬀerent p53 status. We
found that ING2a siRNA required the presence of wild type
p53 for eﬀective growth suppression, while ING2b siRNA
did not show any growth suppressive activity (Fig. 5A). This
growth suppressive eﬀect was not mediated by stabilization
of p53, since the total amount of p53 protein was not changed
by ING2a knockdown (Fig. 5B). ING2 common siRNA sup-
pressed cell growth both in the p53 wild type cells and in the
p53-mutant cells. Thus, down-regulation of ING2 may circum-
vent the resistance of p53-mutant cells to cell death. Under the
microscope, we observed a large percentage of dead cells upon
treatment with ING2 common siRNA in U-2 OS and U-118
MG cells, while M059K and A549 cells simply stopped divid-
ing. Such phenotypes became apparent after the second con-
secutive siRNA transfection. These observations were
conﬁrmed by TUNEL assay (Supplemental Fig. S4). There
was no relationship observed between these phenotypes and
p53 status. We also examined the cell cycle in these cells after0
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Fig. 4. Speciﬁc knockdown of ING2a and ING2b by siRNAs. Cells were tran
(ING2b si), and ING2 common siRNA (ING2 si) on the ﬁrst and fourth day
was examined by TaqMan-PCR. b2-microglobulin RNA was used for norm
diﬀerent p53 status and four other cell lines. (B) Expression level of ING2b6 days of transfection (Supplemental Fig. S5). Although the re-
sult was not very clear, we observed a tendency of the ING2
common siRNA to increase the subG1 population compared
with the ING2a siRNA in all the cell lines that we examined.
However, the subG1 population was increased more than
20% only in U-2 OS and U-118 MG cells by the ING2 com-
mon siRNA transfection, concordant with the result of the
TUNEL assay. We removed dead cells that had died during
the ﬁrst few days by changing cell culture media, thus we mea-
sured the cell cycle only in the surviving cells on the 6th day.
We think that this is the reason why the cell cycle of ING2a
siRNA transfected cells and that of ING2b siRNA transfected
cells were not so diﬀerent.4. Discussion
Recently, we identiﬁed two p53 binding sites in the promoter
region of ING2 (ING2a in this article) [7]. We found that p53
down-regulates ING2a expression through direct binding to
these sites when senescence is induced by mutlin-3a in normal
human ﬁbroblasts. In the present study, we identiﬁed a novel
ING2 isoform, ING2b. The ING2b promoter does not possess
p53 binding sites, suggesting diﬀerential regulation of the two
isoforms. When p53 was induced by nutlin-3a or adriamycin
treatment, expression of ING2a was signiﬁcantly down-regu-
lated in the presence of p53, while expression of ING2b was
not aﬀected, suggesting that only ING2a is a p53 transcrip-
tional target. We further found that ING2a, but not ING2b,
was down-regulated in normal human ﬁbroblasts during repli-
cative senescence. Activation of p53 is one of the hallmarks of
replicative senescence, and the diﬀerential regulation of ING2a
and ING2b may be important in determining cell fate.
We utilized siRNAs designed to selectively target ING2a or
ING2b or both to address their speciﬁc functions. The ING2aU-2 OS M059K U-118 MG
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cells treated with control siRNA as 1.0. Data are shown as the average with the SD from three independent experiments. Statistical analysis was
carried out by Scheﬀe´s F-test (asterisk shows P < 0.01). (B) Expression of p53 was examined by Western blotting in A549 parental and isogenic cells
using anti-p53 antibody (DO-1) on the sixth day. b-actin was used for loading control.
M. Unoki et al. / FEBS Letters 582 (2008) 3868–3874 3873siRNA suppressed cell growth only in the presence of wild type
p53, on the other hand, the ING2b siRNA did not have any
eﬀect on cell growth. The ING2 common siRNA suppressed
cell growth more eﬀectively than ING2a siRNA and indepen-
dently of p53 status, suggesting that both ING2a and ING2b
suppress cell cycle arrest or apoptosis and compensate for each
others function. We propose a negative feedback loop model
to explain these ﬁndings (Supplemental Fig. 6). We think that
even though p53 is activated by ING2a knockdown, the pres-
ence of ING2b can still prevent cells from apoptosis and cell
cycle arrest, and only moderate suppression of cell growth is
induced under ING2a knockdown in a p53 wild type back-
ground. A molecular mechanism underlying how ING2a
knockdown activates p53 is still unknown. It has been recently
reported that ING2a binds to p53 through its N-terminal un-ique region [6]. The signiﬁcance of this binding is still unclear.
ING2a may hasten p53 degradation, or abrogate p53 activity
through binding or modiﬁcation. The amount of p53 was
not changed by ING2a knockdown in our present result, sug-
gesting that ING2a does not contribute to p53 degradation.
Therefore, we think that the ING2a binding itself may inhibit
p53 activity, or modify p53 and convert it into an inactive
form. If this is the case, ING2a knockdown can enhance p53
activity, and impede cell growth. In p53-mutant cells, cell sur-
vival is equally dependent on ING2a and ING2b function, and
each may compensate for the others absence. In this case,
abrogation of both genes is necessary for induction of apopto-
sis or cell cycle arrest, through a p53-independent mechanism.
This data is encouraging for the development of therapeutic
approaches directed to diminish chemotherapeutic resistance
3874 M. Unoki et al. / FEBS Letters 582 (2008) 3868–3874in the clinic. Although further analysis will be required, we
found that the growth suppressive eﬀect of the combination
of adriamycin and ING2 siRNA is larger than that of the adri-
amycin or ING2 siRNA transfection alone ( Supplemental
Fig. S7), supporting a possibility of ING2 siRNA as a new gen-
eration of cancer therapeutic agent.
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